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Abstract
Objective: This study examined the long-term effectiveness of lithium for the treatment of pediatric bipolar disorder within
the context of combination mood stabilizer therapy for refractory mania and pharmacological treatment of comorbid psy-
chiatric conditions.
Methods: Outpatients, ages 7–17 years, meeting American Psychiatric Association, Diagnostic and Statistical Manual of
Mental Disorders, 4th ed. (DSM-IV) diagnostic criteria for bipolar disorder I (BP-I) (manic or mixed) who demonstrated at
least a partial response to 8 weeks of open-label treatment with lithium (Phase I) were eligible to receive open-label lithium for
an additional 16 weeks (Phase II). Up to two adjunctive medications could be prescribed to patients experiencing residual
symptoms of mania or comorbid psychiatric conditions, following a standardized algorithm.
Results: Forty-one patients received continued open-label long-term treatment with lithium for a mean of 14.9 (3.0) weeks
during Phase II. The mean weight-adjusted total daily dose at end of Phase II was 27.8 (6.7) mg/kg/day, with an average
lithium concentration of 1.0 (0.3) mEq/L. Twenty-five of the 41 patients (60.9%) were prescribed adjunctive psychotropic
medications for residual symptoms. The most frequent indications for adjunctive medications were refractory mania (n = 13;
31.7%) and attention-deficit/hyperactivity disorder (ADHD) (n = 15; 36.6%). At the end of this phase 28 (68.3%) patients met
a priori criteria for response (‡ 50% reduction from Phase I baseline in Young Mania Rating Scale [YMRS] summary score
and a Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2), with 22 (53.7%) considered to be in remission
(YMRS summary score £12 and CGI-Severity score of 1 or 2). These data suggest that patients who initially responded to
lithium maintained mood stabilization during continuation treatment, but partial responders did not experience further
improvement during Phase II, despite the opportunity to receive adjunctive medications. The most commonly reported
(‡20%) adverse events associated with lithium treatment were vomiting, headache, abdominal pain, and tremor.
Conclusions: Lithium may be a safe and effective longer-term treatment for patients with pediatric bipolar disorder who
respond to acute treatment with lithium. Partial responders to acute lithium did not appear to experience substantial symptom
improvement during the continuation phase, despite the possibility that adjunctive medications could be prescribed.
Introduction
Lithium is an extensively researched, benchmark main-tenance treatment for adults with bipolar disorder (Bowden
et al. 2000, 2003; Calabrese et al. 2003; Muzina and Calabrese
2005). Despite its effectiveness in adults, long-term lithium treat-
ment is associated with safety concerns, particularly regarding
decreased renal function (Lepkifker et al. 2004; McCann et al.
2008; Tredget et al. 2010) and hypothyroidism (Zhang et al. 2006;
Barbesino 2010). However, because bipolar disorder is a chronic
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condition (Manzano and Salvador 1993; Judd et al. 2002; Perlis
et al. 2004, 2006; Yatham et al. 2009), long-term treatments are
needed.
There are limited prospective long-term treatment data for bi-
polar disorder in children and adolescents. Prospective data for
lithium as a long-term treatment for pediatric bipolar disorder are
generally restricted to combination pharmacotherapy studies
(Findling et al. 2003; Pavuluri et al. 2004, 2006). Despite the
paucity of longer-term data, several randomized, double-blind,
placebo-controlled trials to evaluate the efficacy of monotherapy
with second generation antipsychotic medications for pediatric
bipolar disorder have found that, although study patients typically
experience symptom amelioration, the majority of study partici-
pants do not meet criteria for full remission (Tohen et al. 2007;
Findling et al. 2009; Haas et al. 2009).
Considering that children and adolescents with bipolar disorder
frequently do not respond to monotherapy, and considering that
bipolar disorder is a highly comorbid condition (Geller et al. 2000;
Findling et al. 2001; Tillman et al. 2003), long-term treatments for
pediatric bipolar disorder are likely to include strategies extending
beyond monotherapy. In fact, treatment with multiple mood sta-
bilizers (Findling et al. 2003), as well as combination mood sta-
bilizer-atypical antipsychotic agent therapy (Kafantaris et al. 2001;
DelBello et al. 2002) have been found to be effective therapeutic
strategies for pediatric bipolar disorder. Further, the addition of a
stimulant to a mood stabilizer for the treatment of comorbid at-
tention-deficit/hyperactivity disorder has demonstrated effective-
ness in children and adolescents with bipolar disorder (Scheffer
et al. 2005; Findling et al. 2007).
The purpose of this study is to describe the long-term effect-
iveness and safety of lithium in pediatric bipolar disorder within
the context of combination mood stabilizer therapy and ad-
junctive treatment of comorbid psychiatric conditions. The work
described herein was conducted under the auspices of the Col-
laborative Lithium Trials, a National Institute of Child Health
and Human Development-funded contract to support research
that will comprehensively test lithium as a potential treatment
for pediatric patients with bipolar disorder I (BP-I) (Findling
et al., 2008).
Methods
The data presented herein were collected as part of a 16-week,
open-label long-term effectiveness trial (Phase II) that followed a
preliminary 8 week, open-label, randomized, escalating dose study
(Phase I) that has been described elsewhere (Findling et al. 2011).
Patients were seen at baseline (Week 8 of Phase I) and at study
weeks 1, 2, 4, 6, 8, 10, 12, and 16/end of study (EOS). The In-
stitutional Review Boards for Human Investigation at each of the
multiple study sites approved the procedures of this outpatient
study. Written informed consent was obtained from the subjects’
guardians and written assent was obtained from the subjects before
any study-related procedures were performed.
Subjects
Subjects from Phase I continued to be study eligible if after 8
weeks of open lithium monotherapy treatment they demonstrated
at least a 25% reduction in Young Mania Rating Scale (YMRS)
(Young et al. 1978) score and a Clinical Global Impressions-
Improvement (CGI-I) (National Institute of Mental Health 1985a)
score £3 (at least ‘‘minimally improved’’), and were able to
tolerate at least 600 mg/day of lithium carbonate. To be enrolled in
Phase I, subjects had to be between the ages of 7 and 17 (inclusive)
and meet diagnostic criteria for BP-I, manic or mixed, without
active psychotic symptoms. Subjects were required to be in good
physical health, and be capable of swallowing study medication
(lithium carbonate capsules) whole. For a complete listing of
the inclusion/exclusion criteria for Phase I, please see Findling
et al. (2011).
Diagnostic procedures
Eligible study subjects underwent a psychiatric interview with a
board-certified or board-eligible child and adolescent psychiatrist.
Additionally, subjects were assessed by an interviewer trained on
study-specific procedures using the Schedule for Affective Dis-
orders and Schizophrenia for School Aged Children-Present and
Lifetime Version (K-SADS-PL) (Kaufman et al. 1997) to confirm
the clinician’s diagnosis. The end of the previous lithium trial
(Phase I) served as baseline for this continuation study (Phase II).
Pharmacotherapy
During Phase I, subjects weighing <30 kg received a starting
dose of 300 mg (Arm I). Subjects weighing ‡30 kg were randomly
assigned to receive either a starting dose of 600 mg (Arm I) or
900 mg (Arm II) of lithium. Lithium dose could be increased
weekly by 300 mg, based on the subject’s response and tolerability.
The randomization methods for assignment into Arms I and II are
described elsewhere (Findling et al. 2011). Arms I and II were run in
parallel; Arm III was opened after 8 of the first 10 patients in Arm II
completed 8 weeks of treatment and were determined to have tol-
erated the study drug. Once Arm III was opened, subjects weighing
‡30 kg were randomly assigned to Arms I, II, or III until each arm
was filled. The starting dose for Arm III was 900 mg, increasable by
300 mg every 3 days, based on response and tolerability.
The same dosage of lithium used at the conclusion of Phase I was
maintained at the onset of Phase II. Subsequent dosage modifica-
tions were made using the procedures described previously. The
dose was maintained in order to sustain a recommended trough
level between 0.8 and 1.2 mEq/L, unless side effects precluded this
level. The maximum level after which dose increases were not
permitted was 1.4 mEq/L. Dosing was flexible, and it was based
upon the achievement of the target serum level, apparent benefit,
and apparent tolerability. Dose reductions or increases could be
made at any time as clinically indicated. In order to accurately
assess trough levels, lithium serum concentration was obtained
after a minimum of 7 days after a dose change.
Adjunctive medication
At any time during this phase, up to two adjunctive medications
were allowed to be prescribed to patients, following a standardized
algorithm (see Table 1). The algorithm was developed via con-
sensus process during an investigator meeting in 2006, using the
best available evidence at the time (Findling et al. 2008). The al-
gorithm included a sequence of medications to treat residual
symptoms of psychosis, mania and hypomania, depression, anxi-
ety, and attention-deficit/hyperactivity disorder (ADHD), priori-
tized in that order and based upon patient need. It is of note that only
one mood stabilizer could be used adjunctively at a time. During
this study, the treating physician could prescribe either lorazepam
or hydroxyzine as a rescue medication for sleeplessness and agi-
tation. Neither medication counted toward the maximum of two
allowable adjunctive medications.
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Safety assessments
Side effects were assessed at every study visit by direct, open-
ended query of the subjects and guardians with ascertainment fa-
cilitated using the Side Effects Form for Children and Adolescents
(SEFCA) (Klein et al. 1994), supplemented by specific items from
the UKU Side Effect Rating Scale (Lingjærde et al. 1987) and the
Safety Monitoring and Uniform Report Form (SMURF) (Greenhill
et al. 2004). Neurological side effects were assessed using the
Neurological Examination for Lithium (NELi) (Findling et al.
2008) and the Neurological Rating Scale (NRS) (Simpson and
Angus 1970). The adverse events reported in the results are a
summation of all ascertained events, regardless of methodology,
that were determined by the study team to be adverse events.
Blood pressure, pulse, and weight were measured at each study
visit. Comprehensive physical examinations, including measure-
ment of height were performed at baseline and EOS participation.
A fasting comprehensive chemistry profile, lipid profile, thyroid
profile, urinalysis, and urine toxicology screen were performed at
baseline and EOS. These assessments were also performed, non-
fasting, at week 8. Additionally, a non-fasting complete blood
count with differential and a comprehensive chemistry profile were
performed at week 4. In order to monitor renal function, creatinine
clearance was measured at baseline, week 8, and week 16/EOS.
Females of childbearing potential received a urine and serum
pregnancy test at baseline, week 8, and week 16/EOS.
Outcome measures
At each visit, psychometric outcome measures including the
YMRS, Children’s Depression Rating Scale-Revised (CDRS-R)
(Poznanski et al 1984), Clinical Global Impressions-Severity (CGI-
S) (National Institute of Mental Health 1985a), and CGI-I were
obtained. In addition, completed at baseline and weeks 4, 8, and 16/
EOS, were the Children’s Global Assessment Scale (CGAS) (Shaffer
et al. 1983), Irritation, Depression, and Anxiety Scale (IDA) (Snaith
et al. 1978), Brief Psychiatric Rating Scale (BPRS) (Hughes et al.
2001), Pediatric Anxiety Rating Scale (PARS) (Research Units on
Pediatric Psychopharmacology Anxiety Study Group 2002), Parent
General Behavior Inventory-10 Item Mania Scale (PGBI-10M)
(Youngstrom et al. 2008), Nisonger Child Behavior Rating Form-
TIQ (NCBRF-TIQ) (Aman et al. 2008), and the ADHD Rating Scale
(ARS-IV) (DuPaul et al. 1998). The Caregiver Strain Questionnaire
(CSQ) (Brannan et al. 1997) was completed at baseline and weeks 8
and 16/EOS. Inter-rater reliability was established and maintained
with quarterly assessments for the YMRS and CDRS-R.
Response criteria
At the end of 16 weeks of treatment, all subjects were assessed
and categorized as partial responders, responders, or non-re-
sponders based on a priori criteria. If a subject’s YMRS score was
reduced 25–49% from Phase I baseline and the subject’s CGI-I
score was £3, then the subject was considered a ‘‘partial re-
sponder.’’ If a subject’s YMRS score decreased by ‡50% from
Phase I baseline and the subject’s CGI-I score was a 1 (very much
improved) or 2 (much improved), then the subject was considered a
‘‘responder.’’ Remission was defined as a YMRS summary
score £12 and CGI-I score equal to 1 (very much improved) or 2
(much improved).‘‘Non-response’’ criteria included a YMRS score
reduction <25% or a CGI-I score ‡4.
Results
Study participants
One hundred and five patients were screened for possible open-
label acute treatment with lithium (Phase I). Of the 61 patients who
received study medications during Phase I, 60 youth completed at
least 1 week of treatment and returned for a post-baseline assess-
ment. Forty-one patients completed Phase I and entered the open-
label long-term effectiveness phase (Phase II). The average
treatment duration in Phase II was 14.9 (3.0) weeks. Patient par-
ticipation through Phase I and Phase II is outlined in Figure 1.
Demographic information for the 41 patients who participated in
Phase II, the primary focus of this report, is shown in Table 2.
Lithium dosing and concomitant psychotropic
medications
At the beginning of Phase II, the mean total daily dose of lithium
was 1441.5 (SD = 362.6) mg, whereas the mean weight-adjusted total
daily dose was 28.2 (6.7) mg/kg/day with an average lithium concen-
tration of 1.1 (0.3) mEq/L. The mean total daily dose at EOS partici-
pation was 1470.7 (384.2) mg, whereas the mean weight-adjusted total
Table 1. Concomitant Psychotropic Medication Treatment During Phase II
Rationale Entry criteria First line Second line Third line Other
Psychosis
n = 1
Score ‡ 3 on one of the key positive
psychotic items of Brief Psychiatric


























































aProtocol deviation: patient was prescribed concomitant aripiprazole the reason for which was not discernable.
ADHD, attention-deficit/hyperactivity disorder.
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daily dose at EOS participation was 27.8 (6.7) mg/kg/day, and there
was an average lithium concentration of 1.0 (0.3) mEq/L.
Of the 41 patients receiving long-term treatment with lithium, 25
(60.9%) were prescribed concomitant psychotropic medications for
residual symptoms as allowed by the protocol. More specifically, 1
patient was treated for residual psychosis, 13 for refractory mania, 2 for
comorbid anxiety symptoms, and 15 for comorbid ADHD. No patients
were treated for a depressive episode. Table 1 outlines the number of
patients receiving each concomitant psychotropic medication.
Symptomatic response
A summary of the outcome measure scores for all patients is
provided in Table 3. Table 4 lists the overall and EOS measures for
patients who received adjunctive psychotropic medication to those
that did not, and Table 5 compares overall and EOS measures for
patients who were treated for refractory mania with those who were
not. Although there was no association with the YMRS change
score by lithium dose or lithium concentration at the beginning of
Phase II participation or patient age (p > 0.05), an association be-
tween YMRS score and gender was found. The mean change in
YMRS score for females was 2.26 (7.51) compared with - 2.57
(6.22) for males (p = 0.03).
The YMRS summary percentage improvement showed that the
vast majority of patients (30 patients; 73.2%) had a ‡ 50% decrease
in their YMRS summary score when compared with Phase I
baseline. Further, the analysis of the CGI-I (overall illness) at the
end of Phase II showed that 33 (80.5%) patients were considered to
Enrolled in  
Phase II (N = 41) 
Did not complete Phase II (N = 20) 
Reason for discontinuation: 
Inadequate symptom amelioration (n = 9) 
Investigator decision (n = 1) 
Lack of efficacy (n = 2) 
Patient incarcerated (n = 1) 
Protocol nonadherence (n = 2) 
Withdrew consent (n = 5) 
Enrolled in 
Phase I (N = 61) 
Did not enroll (N = 44) 
Reason: 
Did not meet diagnostic/severity criteria (n = 21) 
Unacceptable use of exclusionary 
medications/treatments (n = 2) 
Lost to follow-up (n = 5) 
Parent withdrew consent (n = 3) 
Subject withdrew consent (n = 3) 
Other (n = 10) 
Screened for possible open-
label acute treatment with 
lithium (Phase I) (N = 105)  
Completed 
Phase I (N = 41) 
Did not complete Phase I (N = 20) 
Reason for discontinuation: 
Adverse event (n = 3) 
Investigator decision (n = 2) 
Lack of efficacy (n = 4) 
Lost to follow-up (n = 1) 
Protocol nonadherence (n = 4) 
Withdrew consent (n = 6) 
Completed 
Phase II (N = 21) 
FIG. 1. Subject accountability.
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be either ‘‘much improved’’ (score of 2) or ‘‘very much improved’’
(score of 1) compared with Phase I baseline. Three (42.9%) of the
seven patients whose YMRS summary score decreased 25–50%
were considered to be ‘‘much improved’’ (based upon CGI-I score
of 2) compared with Phase I baseline.
At the end of Phase II, 28 (68.3%) patients met a priori criteria
for response (‡ 50% reduction from Phase I baseline in YMRS
summary score and a CGI-I score equal to 1 [very much improved]
or 2 [much improved]), whereas 9 (22.0%) patients were consid-
ered to be partial responders (25–50% reduction from baseline in
YMRS summary score and a CGI-I score £3, or ‡50% reduction
from Phase I baseline in YMRS summary score and a CGI-I score
of 3). The remaining four, or 9.7%, were non-responders. At the end
of Phase II, 22 (53.7%) were considered to be in remission (YMRS
summary score £12 and CGI-I score equal to 1 ([very much im-
proved] or 2 [much improved]).
Lithium tolerability
No suicides or deaths occurred during this study, and no patients
discontinued study medication as the result of an adverse event.
Forty (98%) out of 41 patients experienced at least one new
treatment-emergent adverse event (TEAE) during Phase II, as
reported by the SEFCA. Twenty-one (51%) patients experienced a
new TEAE that was considered to be probably related to lithium,
and 15 (37%) patients experienced a new TEAE that was consid-
ered to be possibly related. No patients experienced serious TEAEs.
The most commonly experienced new AEs reported during Phase II
are listed in Table 6.
Selected laboratory measurements obtained during Phase II are
listed in Table 7. The mean thyrotropin concentration decreased
from 5.9 (3.6) mIU/L at the beginning of Phase II to 5.0 (2.9) mIU/L
at the end of Phase II (p = 0.12). Four patients had a thyrotropin
concentration >10 mIU/L at Phase II baseline. During the course of
Phase II, four other patients were found to have a thyrotropin
concentration >10 mIU/L at one or more time points.
The mean white blood cell count was 8.0 (1.9) · 10E9/L at the
beginning of Phase II and 8.0 (2.3) · 10E9/L at the end of Phase II
(p = 0.98). The mean neutrophil percentage decreased from 60.1%
(7.6) at the beginning of Phase II to 54.5% (16.0) at the end of Phase
II (p = 0.03). The mean estimated creatinine clearance at the be-
ginning of Phase II for these study participants was 115.7 (28.6)
mL/min, and at end of Phase II was 121.6 (36.7) mL/min (p = 0.11).
While enrolled in Phase II, study participants experienced a
statistically significant mean weight gain of 1.58 (3.85) kg (Phase II
baseline weight: 53.88 (17.47) kg; end of Phase II weight: 55.46
(17.69) kg; p = 0.013). Body mass index did not significantly in-
crease during study participation.
In addition, there was a subset of patients who had fasting lipid
measurements obtained. Only a subset of patients had these




Mean (SD) age at Phase I baseline 11.8 (2.8)
Sex (male) 22 (54%)
Race
Caucasian 34 (83%)
African American 5 (12%)
Caucasian/African American 2 (5%)
Age of onset of bipolar disorder, years 9.1 (3.3)
Mood state at Phase I study entry
Manic 18 (44%)
Mixed 23 (56%)
Length of bipolar disorder illness, years at
Phase I baseline
2.3 (2.6)
Current psychiatric comorbid diagnoses
Any ADHDa 29 (71%)
Any DBDb 11 (27%)
Any anxiety disorderc 9 (22%)
Mean (SD) weight-adjusted total daily
lithium dose at Phase II entry
28.2 (6.7) mg/kg/day
Mean (SD) lithium concentration at
Phase II entry
1.1 (0.3) mEq/L
Mean length (weeks) of study
participation in Phase II
14.9 (3.0)
aADHD, attention-deficit/hyperactivity disorder; ADHD-combined;
ADHD-hyperactive/impulsive; ADHD-inattentive; ADHD-not otherwise
specified.
bDBD, disruptive behavior disorder; conduct disorder; oppositional
defiant disorder.
cGeneralized anxiety disorder; panic disorder; posttraumatic stress disor-
der; social anxiety disorder; social phobia; specific phobia. Three patients
met diagnostic criteria for more than one anxiety disorder.
Table 3. Change in Mean Outcome Measure
Scores during Phase II
Total participants
Measure (n = 41) p
YMRS
Phase I baseline score Mean (SD) 30.2 (5.9)
Phase II baseline score Mean (SD) 9.8 (6.3) 0.77
EOS score Mean (SD) 9.4 (7.4)
Change score Mean (SD) - 0.3 (7.2)
CDRS-R
Phase I baseline score Mean (SD) 39.5 (12.4)
Phase II baseline score Mean (SD) 24.0 (5.3) 0.24
EOS score Mean (SD) 22.9 (6.2)
Change score Mean (SD) - 1.1 (6.2)
CGAS
Phase I baseline score Mean (SD) 49.6 (6.8)
Phase II baseline score Mean (SD) 67.6 (14.1) 0.36
EOS score Mean (SD) 69.0 (13.1)
Change score Mean (SD) 1.4 (9.8)
CGI-S (Mania)
Phase I baseline score Mean (SD) 4.6 (0.6)
Phase II baseline score Mean (SD) 2.3 (1.0)
EOS score Mean (SD) 2.2 (1.1) 0.51
Change score Mean (SD) - 0.1 (0.9)
CGI-S (Depression)
Phase I baseline score Mean (SD) 3.2 (1.2)
Phase II baseline score Mean (SD) 1.7 (0.9) 0.64
EOS score Mean (SD) 1.8 (0.9)
Change score Mean (SD) 0.1 (1.0)
CGI-S (Overall Illness)
Phase I baseline score Mean (SD) 4.6 (0.6)
Phase II baseline score Mean (SD) 2.4 (0.9) 0.23
EOS score Mean (SD) 2.2 (1.1)
Change score Mean (SD) - 0.2 (1.0)
YMRS, Young Mania Rating Scale; CDRS-R, Child Depression Rating
Scale Revised; CGAS, Children’s Global Assessment Scale; CGI-S,
Clinical Global Impressions-Severity; EOS, end of study.
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assessments made owing to the substantial number of patients who
were not fasting at the end of Phase II participation. With the
exception of increased cholesterol/ high-density lipoprotein (HDL)
ratio (Phase II baseline: 3.4 [1.1]; end of Phase II: 3.7 [1.2];
p = 0.03), there were no statistically significant changes in lipid
measurements during Phase II participation (Table 7).
Other psychometric measures
Mean (SD) scores at Phase I baseline, Phase II baseline, and end
of week 16/end of Phase II for ARS-IV, BPRS-C, CSQ, PGBI-10M,
IDA, NCBRF-TIQ, and PARS are summarized in Table 8. Table 9
compares the psychometric measure scores for patients who re-
ceived adjunctive psychotropic medication with those who did not
receive adjunctive psychotropic medication, and Table 10 com-
pares psychometric measure scores for patients treated for refrac-
tory mania with those of patients who were not treated for
refractory mania (i.e., treated for another comorbid condition or did
not receive any adjunctive medications).
The comparisons summarized in Table 10 suggest that patients
not treated for refractory mania were generally less symptomatic
at Phase II baseline than those patients who were treated. Further,
patients who were treated for refractory mania often worsened
with time, whereas those who were not treated for refractory
mania generally improved with time. Significant improvements in
caregiver strain (p = 0.02) and parent-rated manic symptoms
(p = 0.03) were noted in patients who did not receive adjunctive
medications for refractory mania. Conversely, caregiver strain
significantly increased (p = 0.03) and irritability worsened to a
nearly significant degree (p = 0.05) in patients treated for refrac-
tory mania.
Discussion
The goals of this study were to evaluate both the durability of the
effectiveness and long-term safety of lithium in children and ado-
lescents who were at least partial responders to 8 weeks of open-
label lithium treatment. This study contributes to the existing
literature (Findling and Pavuluri 2008) pertaining to the long-term
effectiveness data for lithium in pediatric bipolar disorder, the body
of which is relatively small. Only a few pediatric studies have
prospectively evaluated lithium as a long-term treatment for bipolar
disorder, and these data are generally limited to combination
pharmacotherapy studies (Findling et al. 2003; Pavuluri et al. 2004,
2006).
An additional goal of this study was to explore the pattern of use
and need for adjunctive treatment for refractory symptoms of mania
and/or coexisting conditions, most frequently ADHD. Overall,
patients remained stable, rather than improving during this phase,
despite the addition of adjunctive medications in the majority of
patients. However, comparison of psychometric measure scores for
patients receiving adjunctive psychotropic medication for refrac-
tory mania with those of patients who did not receive adjunctive
psychotropic medication for refractory mania reveal possible
Table 4. Change in Mean Outcome Measure Scores during Phase II: Comparison of Participants Receiving
Adjunctive Psychotropic Medications with Participants not Receiving Adjunctive Psychotropic Medications
No adjunctive psychotropic
medications n = 16
Adjunctive psychotropic











Phase II baseline score Mean (SD) 8.2 (5.4) 10.8 (6.8)
EOS score Mean (SD) 8.7 (8.2) 0.76 9.9 (7.0) 0.56 1.4 (7.2) 0.55
Change score Mean (SD) 0.5 (6.8) - 0.9 (7.5)
CDRS-R
Phase II baseline score Mean (SD) 24.8 (5.1) 23.5 (5.4)
EOS score Mean (SD) 23.6 (7.1) 0.49 22.4 (5.7) 0.35 - 0.2 (6.3) 0.93
Change score Mean (SD) - 1.2 (7.1) - 1.1 (5.7)
CGAS
Phase II baseline score Mean (SD) 67.5 (14.4) 69.7 (14.2)
EOS score Mean (SD) 69.2 (13.2) 0.48 68.9 (13.5) 0.55 0.5 (9.9) 0.86
Change score Mean (SD) 1.7 (9.8) 1.2 (10.0)
CGI-S (Mania)
Phase II baseline score Mean (SD) 2.2 (0.9) 2.4 (1.0)
EOS score Mean (SD) 2.2 (1.1) 1.00 2.2 (1.1) 0.46 0.2 (0.9) 0.60
Change score Mean (SD) 0 (0.7) - 0.2 (1.1)
CGI-S (Depression)
Phase II baseline score Mean (SD) 1.9 (1.0) 1.7 (0.8)
EOS score Mean (SD) 2.1 (0.9) 0.48 1.7 (0.9) 1.00 0.2 (1.0) 0.56
Change score Mean (SD) 0.2 (1.0) 0.0 (1.0)
CGI-S (Overall Illness)
Phase II baseline score Mean (SD) 2.4 (0.9) 2.4 (1.0)
EOS score Mean (SD) 2.2 (1.1) 0.42 2.2 (1.1) 0.38 0.0 (1.0) 0.97
Change score Mean (SD) - 0.2 (0.9) - 0.2 (1.1)
YMRS, Young Mania Rating Scale; CDRS-R, Child Depression Rating Scale Revised; CGAS, Children’s Global Assessment Scale; CGI-S, Clinical
Global Impressions-Severity; EOS, end of study.
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trends, some of which are noteworthy. For example, patients who
were only partial responders to lithium had some aspects of their
clinical status that worsened with time, whereas those who were
responders to lithium had some parameters that improved with
time, suggesting that the need for adjunctive medication may be an
overall sub-optimal prognostic indicator.
Further, over time, for some patients, either adjunctive psy-
chosocial interventions or more than one psychotropic agent may
be required to achieve and maintain manic symptom amelioration
in pediatric bipolar disorder. This result is not surprising, as several
double-blind, placebo-controlled trials of antipsychotic medica-
tions for the acute treatment of children and adolescents with bi-
polar disorder have also found that the majority of study
participants do not experience full remission with drug mono-
therapy (Tohen et al. 2007; Findling et al. 2009; Haas et al. 2009). It
is surprising that treatment with adjunctive mood stabilizer medi-
cation did not seem to make a notable impact upon symptom
amelioration in this cohort. However, our choice of divalproex
sodium as the first-line treatment for refractory mania, which was
based on the best available data at the time this study was designed,
may have played a role in the lack of improvement. Based on data
from monotherapy studies, other agents, such as the second gen-
eration antipsychotic medications, might have proven to have been
more efficacious as adjunctive treatments for those youth who did
not respond to initial treatment with lithium monotherapy (Tohen
et al. 2007; Findling et al. 2009; Haas et al. 2009; Wagner et al.
Table 5. Change in Mean Outcome Measure Scores during Phase II: Comparison of Participants Receiving
Adjunctive Psychotropic Medications for Refractory Mania with Participants Not Receiving Adjunctive
Psychotropic Medications for Refractory Mania
No adjunctive psychotropic
medications for refractory
mania n = 28
Adjunctive psychotropic
medications for refractory
mania n = 13
Mean difference in
change scores
Measure Total participants p Total participants p Mean (SD) p
YMRS
Phase II baseline score Mean (SD) 9.1 (6.1) 11.1 (6.8)
EOS score Mean (SD) 8.2 (7.4) 0.51 12.1 (7.0) 0.64 - 1.8 (7.2) 0.45
Change score Mean (SD) - 0.9 (7.3) 0.9 (7.0)
CDRS-R
Phase II baseline score Mean (SD) 23.5 (5.0) 25.1 (5.9)
EOS score Mean (SD) 22.7 (6.4) 0.50 23.1 (6.2) 0.32 1.1 (6.2) 0.59
Change score Mean (SD) - 0.8 (6.1) - 1.9 (6.7)
CGAS
Phase II baseline score Mean (SD) 68.2 (14.9) 66.3 (12.7)
EOS score Mean (SD) 70.0 (12.9) 0.32 67.1 (13.9) 0.81 0.9 (9.9) 0.78
Change score Mean (SD) 1.7 (9.0) 0.8 (11.5)
CGI-S (Mania)
Phase II baseline score Mean (SD) 2.2 (1.0) 2.5 (1.0)
EOS score Mean (SD) 2.1 (1.1) 0.57 2.5 (1.2) 0.75 0.0 (1.0) 0.92
Change score Mean (SD) - 0.1 (1.0) - 0.1 (0.9)
CGI-S (Depression)
Phase II baseline score Mean (SD) 1.7 (0.9) 1.8 (0.8)
EOS score Mean (SD) 1.9 (0.8) 0.44 1.8 (1.1) 0.79 0.2 (1.0) 0.51
Change score Mean (SD) 0.1 (1.0) - 0.1 (1.0)
CGI-S (Overall Illness)
Phase II baseline score Mean (SD) 2.3 (0.9) 2.5 (1.0)
EOS score Mean (SD) 2.1 (1.1) 0.24 2.5 (1.2) 0.75 - 0.2 (1.1) 0.62
Change score Mean (SD) - 0.1 (0.9) - 0.2 (1.1)
YMRS, Young Mania Rating Scale; CDRS-R, Child Depression Rating Scale Revised; CGAS, Children’s Global Assessment Scale; CGI-S, Clinical
Global Impressions-Severity; EOS, end of study.
Table 6. Most Frequently Occurring (‡ 10% of Total
Patients) Treatment-Emergent Adverse Events
of New Onset during Phase II
Medical Dictionary for Regulatory Activities
(MedDRA) System Organ Class/Preferred Term Total (%)
Gastrointestinal disorders
Vomiting 17 (42)
Abdominal pain upper 10 (24)
Nausea 6 (15)
General disorders and administration site conditions
Thirst 7 (17)
Metabolism and nutrition disorders







Initial insomnia 5 (12)
Renal and urinary disorders
Enuresis 7 (17)
Skin and subcutaneous tissue disorders
Acne 4 (10)
Rash 4 (10)
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2009; Geller et al. 2012). Future research on the effectiveness and
tolerability of individual adjunctive medications within this study
population may provide salient information regarding the treatment
of pediatric bipolarity.
A small between-gender difference was found on change in
YMRS scores during this trial. Importantly, there was no significant
between-gender difference in YMRS scores at Phase II baseline
(YMRS score for females = 8.84 [6.73] compared with 10.55 [6.01]
for males [p = 0.40]). Therefore this between-gender difference in
YMRS score change could be a chance finding that is likely not to
be clinically significant.
Long-term treatment with open-label lithium was generally safe
and well tolerated. Thyrotropin levels were closely monitored
throughout the study, as lithium has been found to be associated
with significant rates of thyrotropin elevation in pediatric bipolar
disorder (Gracious et al. 2004). Although a few patients experi-
enced clinically significant changes in and/or elevated thyroid-
related laboratory values during Phase II, none of these patients
suffered from a thyroid-related adverse event. Renal function was
also closely monitored throughout the study. No significant
changes in creatinine clearance were found during this study, and
no patients discontinued treatment as a result of decreased renal
function.
A primary limitation of this study is its open, uncontrolled de-
sign. This study is further limited by its relatively small sample
size. Additionally, study participants received lithium for 16 weeks,
whereas treatment for pediatric bipolar disorder will generally
extend beyond 16 weeks.
Conclusions
Data from this open-label long-term effectiveness study suggest
that lithium may be a safe, tolerable, and effective treatment option
for pediatric bipolar disorder following mood stabilization with
lithium. It is important to note, however, that overall, these patients
maintained mood stabilization, rather than experiencing further
improvement during this study, despite the opportunity to receive
adjunctive medications. The subset of patients requiring adjunctive
treatment for refractory mania had some aspects of their clinical
status that worsened during study participation. This observation
suggests that more effective treatment strategies are needed for this
vulnerable patient population. Furthermore, longer studies that can
more definitively evaluate the efficacy of lithium for the long-term
treatment of pediatric bipolar disorder are needed.
Table 7. Selected Physiologic Measurements








5.9 (3.6) 5.0 (2.9) 0.12
White blood cell count
(·10E9/L)
8.0 (1.9) 8.0 (2.3) 0.98
Neutrophil percentage (%) 60.1 (7.6) 54.5 (16.0) 0.03
Estimated creatinine
clearance (mL/min)
115.7 (28.6) 121.6 (36.7) 0.11
Weight (kg) 53.88 (17.5) 55.46 (17.7) 0.013
Body mass index (kg/m2) 22.52 (4.7) 22.80 (4.8) 0.24
Fasting LDL (mg/dL) n = 18 93.8 (33.2) 89.5 (21.2) 0.48
Fasting HDL(mg/dL) n = 18 51.4 (14.9) 57.4 (13.9) 0.11
Fasting cholesterol
(mg/dL) n = 27
163.6 (38.9) 156.8 (28.9) 0.21
Fasting cholesterol/HDL
ratio n = 18
3.4 (1.1) 3.7 (1.2) 0.03
Fasting triglyceride
(mg/dL) = 28
96.7 (61.8) 106.5 (64.6) 0.27
aData presented as mean (standard deviation).
LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Table 8. Change in Other Psychometric Measure Mean Scores during Phase II
Phase I baseline Phase II baseline End of Phase II
Instrument Mean (SD) Mean (SD) p Mean (SD) p
ADHD Rating Scale-IV (ARS-IV)
Total score 34.4 (12.0) 28.8 (11.6) 0.002 27.9 (13.3) 0.59
Inattention 19.0 (6.2) 17.0 (5.7) 0.04 16.1 (6.7) 0.41
Hyperactivity-Impulsivity 15.4 (6.7) 11.9 (6.8) < 0.0001 11.8 (7.5) 0.84
Brief Psychiatric Rating Scale for Children (BPRS-C)
Total score 33.2 (9.9) 12.8 (7.7) < 0.0001 12.7 (9.2) 0.92
Caregiver Strain Questionnaire (CSQ)
Total score 65.7 (16.7) 53.5 (19.3) 0.0003 51.5 (17.8) 0.52
Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M)
Total score 17.5 (6.5) 9.1 (6.5) < 0.0001 8.0 (7.7) 0.37
Irritability, Depression, and Anxiety (IDA)
Total score 9.8 (1.8) 4.1 (3.1) < 0.0001 5.0 (4.2) 0.14
Nisonger Child Behavior Rating Form-TIQ (NCBRF-TIQ)
Conduct Problem 22.2 (5.7) 17.0 (5.1) < 0.0001 16.5 (4.8) 0.38
ADHD-Total 13.5 (4.2) 9.5 (4.0) < 0.0001 9.2 (4.2) 0.51
Pediatric Anxiety Rating Scale (PARS)
Total score with five items 4.7 (6.2) 3.4 (5.8) 0.14 2.0 (4.5) 0.15
ADHD, attention-deficit/hyperactivity disorder.
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Table 9. Change in Other Psychometric Measures Mean Scores During Phase II: Comparison of Participants Receiving
Adjunctive Psychotropic Medications with Participants Not Receiving Adjunctive Psychotropic Medications
No adjunctive psychotropic
medications n = 16
Adjunctive psychotropic











Instrument Mean (SD) Mean (SD) p Mean (SD) Mean (SD) p Mean (SD) p
ADHD Rating Scale-IV (ARS-IV)
Total score 23.9 (9.4) 21.3 (11.3) 0.14 32.0 (11.9) 32.3 (12.9) 0.99 2.6 (12.0) 0.45
Inattention 14.8 (4.9) 13.1 (5.7) 0.11 18.3 (5.9) 18.2 (6.6) 0.89 1.5 (6.3) 0.40
Hyperactivity-Impulsivity 9.1 (5.7) 8.2 (6.6) 0.36 13.7 (6.9) 14.1 (7.3) 0.89 1.0 (6.2) 0.56
Brief Psychiatric Rating Scale for Children (BPRS-C)
Total score 11.7 (7.7) 10.7 (6.9) 0.61 13.6 (7.8) 14.0 (10.3) 0.87 - 1.5 (10.7) 0.67
Caregiver Strain Questionnaire (CSQ)
Total score 49.1 (19.9) 44.1 (11.0) 0.21 56.3 (18.8) 56.1 (19.9) 0.99 - 4.9 (18.0) 0.41
Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M)
Total score 6.9 (6.5) 4.5 (4.4) 0.08 10.6 (6.2) 10.4 (8.6) 0.88 - 2.1 (7.9) 0.37
Irritability, Depression, and Anxiety (IDA)
Total score 4.2 (2.9) 5.4 (4.1) 0.10 4.1 (3.3) 4.8 (4.3) 0.44 0.6 (3.8) 0.65
Nisonger Child Behavior Rating Form-TIQ (NCBRF-TIQ)
Conduct Problem 16.0 (6.0) 15.2 (4.5) 0.60 17.7 (4.4) 17.3 (5.0) 0.49 0.0 (5.3) 0.98
ADHD-Total 8.6 (4.7) 7.3 (3.2) 0.27 10.0 (3.4) 10.4 (4.4) 0.97 - 1.3 (4.5) 0.38
Pediatric Anxiety Rating Scale (PARS)
Total score with five items 2.7 (4.5) 2.5 (4.2) 0.75 3.8 (6.5) 1.8 (4.7) 0.17 1.8 (5.9) 0.28
ADHD, attention-deficit/hyperactivity disorder.
Table 10. Change in Other Psychometric Measures Mean Scores During Phase II: Comparison of Participants
Receiving Adjunctive Psychotropic Medications for Refractory Mania with Participants not Receiving
Adjunctive Psychotropic Medications for Refractory Mania
No adjunctive psychotropic
medications for
refractory mania n = 28
Adjunctive psychotropic
medications for












Instrument Mean (SD) Mean (SD) p Mean (SD) Mean (SD) p Mean (SD) p
ADHD Rating Scale-IV (ARS-IV)
Total score 27.4 (11.6) 24.2 (12.4) 0.09 31.9 (11.4) 35.6 (12.1) 0.38 - 7.0 (11.6) 0.08
Inattention 16.5 (5.4) 14.6(6.3) 0.08 18.0 (6.5) 19.5 (6.4) 0.89 - 3.4 (6.1) 0.11
Hyperactivity-Impulsivity 10.9 (7.1) 9.7 (7.0) 0.16 13.9 (5.7) 16.1 (6.6) 0.32 - 3.6 (6.0) 0.08
Brief Psychiatric Rating Scale for Children (BPRS-C)
Total score 12.3 (7.6) 10.6 (6.8) 0.30 14.1 (8.0) 17.1 (12.0) 0.44 - 4.8 (10.5) 0.27
Caregiver Strain Questionnaire (CSQ)
Total score 52.9 (20.5) 44.8 (11.7) 0.02 54.6 (17.0) 65.0 (20.7) 0.03 - 18.3 (15.9) 0.002
Parent General Behavior Inventory-10 Item Mania Scale (PGBI-10M)
Total score 7.9 (6.9) 4.7 (4.2) 0.03 11.7 (4.9) 14.9 (8.8) 0.14 - 6.4 (7.4) 0.01
Irritability, Depression, and Anxiety (IDA)
Total score 4.3 (3.2) 4.3 (3.7) 0.95 3.8 (2.8) 6.5 (4.8) 0.05 - 2.7 (3.6) 0.03
Nisonger Child Behavior Rating Form-TIQ (NCBRF-TIQ)
Conduct Problem 17.1 (5.8) 15.8 (4.0) 0.13 16.8 (3.4) 17.8 (6.2) 0.49 - 2.6 (5.1) 0.14
ADHD-Total 8.9 (4.3) 7.7 (3.0) 0.06 10.7 (2.8) 12.2 (4.8) 0.32 - 3.0 (4.4) 0.05
Pediatric Anxiety Rating Scale (PARS)
Total score with five items 3.1 (5.3) 1.7 (3.4) 0.11 3.9 (6.9) 2.8 (6.3) 0.63 - 0.3 (6.0) 0.91
ADHD, attention-deficit/hyperactivity disorder.
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Clinical Significance
These data add to the modest amount of literature that suggests
that lithium may be a safe, tolerable and effective longer-term
treatment option for children and adolescents with BP-I who
respond to initial lithium treatment. Overall, lithium was gener-
ally well tolerated and associated with maintenance of symptom
amelioration. However, although adjunctive medications could
be prescribed during this study phase, symptomatic patients did
not appear to experience substantial symptom improvement.
Therefore, more effective interventions and longer-term studies
of lithium treatment are needed for this patient population.
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